UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including ...
Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to the class leader.
The interleukin-17 (IL-17) family cytokines are strong inducers of inflammation and help to protect us against invading pathogens. However, they also have a dark side and contribute to the tissue ...
Patients with psoriatic arthritis exhibit high levels of both IL-17A and IL-17F cytokines in the synovium. Bimekizumab, a biologic that targets both IL-17A and IL-17F, was recently approved for the ...
Hosted on MSN11mon
Storms knock out power for approximately 1,200 Ameren Energy customers in the greater QC region Tuesday nightMercer County Towing and Recovery sent in a picture of a downed power line on IL-17 east of Aledo. Additionally in Iowa City, MidAmerican Energy's power outage map said that approximately 1,900 ...
Learn how targeted therapy and advanced blood analysis transformed treatment for erthyroderma, a rare inflammatory skin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results